Clinical Trial Update: Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate the SIIPL QHPV vaccine (CERVAVAC) in women living with HIV aged 15-25; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• CERVAVAC (quadrivalent human papillomavirus vaccine)

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Human Papillomavirus Infection | Phase 3 | Status: NOT_YET_RECRUITING